Rani Therapeutics Holdings, INC

Rani Therapeutics Holdings, Inc. announced the appointment of Michelle Gilson to its Board of Directors and as chair of the Audit Committee, effective August 1, 2026.

Rani Therapeutics Holdings, Inc. announced significant corporate governance changes, including the termination of its Tax Receivable Agreement and a reduction in Class B common stock voting power, effective December 31, 2025.

Rani Therapeutics announced a significant collaboration with Chugai Pharmaceutical, an oversubscribed private placement, and extended its cash runway into 2028, alongside reporting Q3 2025 financial results.

Rani Therapeutics Holdings, Inc. announced the appointment of two new directors and the closing of a private placement, significantly impacting its board composition and capital structure.

Rani Therapeutics Holdings, Inc. announced a $60.3 million private placement, a debt conversion, and a strategic collaboration with Chugai Pharmaceutical for an oral hemophilia product.

Rani Therapeutics announced its second quarter 2025 financial results, highlighted by a new research collaboration with Chugai and progress on its oral obesity treatment, RT-114, despite a significant decrease in cash reserves.

Rani Therapeutics reports Q1 2026 financial results, highlighting ongoing clinical development and a Nasdaq listing deficiency notice.

Rani Therapeutics reported reduced net losses and secured over $75 million in new funding and potential milestones, alleviating prior going concern doubts and advancing its oral drug delivery platform.

Rani Therapeutics Holdings, Inc. reported continued losses and substantial doubt about its ability to continue as a going concern, alongside receiving notices of non-compliance with Nasdaq's minimum bid price and market value requirements.

Rani Therapeutics reports Q1 2025 results with a net loss of $12.7 million and expresses substantial doubt about its ability to continue as a going concern, despite preclinical advancements in its oral drug delivery platform.

Rani Therapeutics reported a net loss of $12.7 million for the third quarter of 2024, with substantial doubt raised about the company's ability to continue as a going concern.

Rani Therapeutics' second quarter 2024 results show a net loss of $13.361 million, with ongoing efforts to advance their oral delivery technology and secure additional funding.

Rani Therapeutics details its 2024 financial results and provides updates on its RaniPill platform and pipeline programs, including collaborations and preclinical data.

Rani Therapeutics focuses on key programs, expands manufacturing, and streamlines operations, including a 25% workforce reduction, to support the RaniPill technology platform.

Mir A Imran, a Director and 10% owner of Rani Therapeutics Holdings, Inc., purchased 36,000 shares of common stock on July 21, 2026 for $0.69 per share.

Alireza Javadi, Chief Technical Officer of Rani Therapeutics Holdings, Inc., sold 386 shares of common stock on March 27, 2026 for $0.78 per share.

Talat Imran, Chief Executive Officer and a Director of Rani Therapeutics Holdings, Inc., purchased 35,000 shares of common stock on July 17, 2026 for $0.72 per share.

Talat Imran, Chief Executive Officer and a Director of Rani Therapeutics Holdings, Inc., sold 8,014 shares of common stock on December 27, 2024 for $1.41 per share.

Nicholas Maestas, Chief Financial Officer of Rani Therapeutics Holdings, Inc., received 2,000,000 shares of common stock on July 17, 2026.

Chief Business Officer Kate McKinley was granted 805,500 stock options in Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on May 28, 2026.

Rani Therapeutics Holdings, Inc. completed a $60.3 million private placement and approved significant corporate governance changes, including reducing Class B voting power and eliminating stockholder written consent, to address financial needs and comply with Nasdaq rules.

Rani Therapeutics Holdings, Inc. announced a private placement transaction where an existing institutional investor exercised warrants at a reduced price, providing $4.3 million in gross proceeds, and received new warrants, with the issuance of underlying shares approved by a majority stockholder to address capital needs and going concern doubt.

Laureen DeBuono has withdrawn her nomination for reelection to the Board of Directors of Rani Therapeutics, effective immediately.

Rani Therapeutics Holdings, Inc. has filed a definitive proxy statement with the SEC.

Rani Therapeutics has announced its annual meeting of stockholders to be held virtually on May 28, 2025, to vote on the election of directors and ratification of the company's independent auditor.

Samsara BioCapital and its affiliates have increased their beneficial ownership in Rani Therapeutics through a $2 million registered direct offering.

Samsara BioCapital entities invest $12 million in Rani Therapeutics through a private placement, gaining a board seat and influencing significant governance changes.

Mir Imran, a key insider, increased his stake in Rani Therapeutics through a private placement, alongside proposed significant corporate governance changes.

South Lake Management and its affiliates have reduced their beneficial ownership in Rani Therapeutics Holdings, Inc. to below 5% through recent open-market sales.

Vanguard Capital Management has reported a beneficial ownership of 4.49% in Rani Therapeutics Holdings Inc. as of June 30, 2026.

SymBiosis Capital Partners, LLC has reported beneficial ownership of 4.4% of Rani Therapeutics Holdings, Inc. Class A Common Stock as of March 27, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.12% of Rani Therapeutics Holdings Inc. common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Rani Therapeutics Holdings Inc. following an internal realignment.

AWM Investment Company, Inc. has disclosed a significant 9.9% beneficial ownership stake in Rani Therapeutics Holdings, Inc. through various funds.

SymBiosis Capital Partners, LLC has reported a 6.5% beneficial ownership stake in Rani Therapeutics Holdings, Inc.'s Class A Common Stock.